News | Stroke | August 28, 2018

iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers

Installations of advanced cerebrovascular imaging platform up 48 percent since April

iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers

August 27, 2018 — iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging platform for cerebrovascular imaging, with 520 currently installed. RAPID technology assists physicians in the analysis of brain images using automated tools for CT ASPECTS, computed tomography (CT) angiography, CT perfusion, magnetic resonance (MR) diffusion and perfusion for more than 85,000 stroke cases per year. RAPID is also currently deployed in six multi-center clinical trials globally.

Under institutional review board (IRB) approval, iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3. Both trials successfully treated stroke patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association and American Stroke Association’s stroke guidelines to include CT perfusion and MR perfusion.

The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.

iSchemaView Senior Vice President Anil Singhal, M.D., noted that several large hospital systems have recently adopted the RAPID platform, including 17 hospitals of Baylor Scott & White Health. Singhal said that by deploying RAPID through in a hub and spoke model, more patients will be able to get the right treatment at the most appropriate facility, vastly improving patient care and at the same time increasing hospital efficiency.

The RAPID neuroimaging platform creates high-quality images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion studies. The software provides an intuitive and easily interpretable real-time view of brain perfusion, allowing physicians to determine lesion volumes for a wide variety of different thresholds.

The platform includes four different imaging products, tailored to the particular needs of each facility:

  • RAPID MRI provides fully automated, easy-to-interpret diffusion and perfusion maps that identify brain areas with low ADC values, as well as delayed contrast arrival. RAPID MRI perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds;
  • RAPID CTP provides CT perfusion maps that automatically quantify regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. Regions are color coded, and the volumes of interest are automatically measured. Maps (including mismatch maps) of the severity of Tmax delays are provided using a four-color-coded scale;
  • RAPID CTA automatically provides clear, easy-to-interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple four-color-coded scale. Additionally, a 3-D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles; and
  • RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE Marked.

For more information: www.i-rapid.com

Related Content

CT Offers Non-Invasive Alternative for Complex Coronary Disease Treatment Planning based on data from the SYNTAX III Trial. The use of FFR-CT in the trial showed better planning for interventional procedures.

CT cffers a non-invasive alternative for complex coronary disease treatment planning based on data from the SYNTAX III Trial. 

News | CT Angiography (CTA) | October 16, 2018
A new study published in the European Heart Journal shows computed tomography (CT) can be a useful aid in heart team...
A comparison of CT image of heavily calcified coronary arteries that appear to present a significant hemodynamic blockages and the correspending FFR-CT showing the patient had adequate blood flow and does not need a diagnostic angiogram or intervention.

A comparison of a CT image of heavily calcified coronary arteries that appear to present a significant hemodynamic blockage and the corresponding FFR-CT showing the patient had adequate blood flow and does not need a diagnostic angiogram or intervention. Image courtesy of Kavitha Chinnaiyan, William Beaumont Hospital.

Feature | CT Angiography (CTA) | July 23, 2018 | Dave Fornell, Editor
The use of non-invasive fractional flow reserve CT (FFR-CT) was the hottest topic discussed at the Society of Cardiov
Videos | CT Angiography (CTA) | July 19, 2018
Kavitha Chinnaiyan, M.D., FACC, FSCCT, associate professor, Oakland University, William Beaumont School of Medicine,
Videos | CT Angiography (CTA) | July 18, 2018
A discussion with Gianluca Pontone, M.D., Ph.D., FSCCT, director of cardiovascular MRI, Centro Cardiologico Manzino,
Videos | CT Angiography (CTA) | July 17, 2018
A discussion with Todd Villines, M.D., FACC, FAHA, FSCCT, director of cardiovascular research and cardiac CT programs
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | CT Angiography (CTA) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
iSchemaView Receives FDA Clearance for Rapid CTA
Technology | CT Angiography (CTA) | May 01, 2018
Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug...
The use of metal artifact reduction software on this CCTA (CTA) cardiac CT from an Canon, Toshiba, Aquilion Precision, allows clear visualization inside a coronary stent. The 0.25 mm high-resolution reconstruction also helps delineate the various components of plaque.

The use of metal artifact reduction software on this Aquilion Precision image allows clear visualization inside a coronary stent. The 0.25 mm high-resolution reconstruction also helps delineate the various components of plaque.

Feature | CT Angiography (CTA) | April 26, 2018 | Dave Fornell
There have been a few big, recent advancements in cardiac computed tomography angiography (CCTA) imaging technology.
Siemens Healthineers, Florida Hospital Collaborate to Improve Healthcare Outcomes
News | CT Angiography (CTA) | January 23, 2018
January 23, 2018 – Siemens Healthineers and Florida Hospital, part of Adventist Health System, have announced a multi
Overlay Init